Mutated or dysregulated transcription factors represent a unique class of drug targets that
mediate aberrant gene expression, including blockade of differentiation and cell death gene …

Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

The acute myeloid leukemia (AML) treatment landscape has changed substantially since
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …

In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of
initiating lesions, and order of subsequent mutations remain poorly understood, as AML is …

PURPOSE The applicability of FLT3-internal tandem duplications (FLT3-ITD) for assessing
measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission …

Approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML) harbor
mutations in the fms-like tyrosine kinase 3 (FLT3) gene. While the adverse prognostic impact …

Acute myeloid leukemia (AML) is a kind of malignant hematopoietic system disease
characterized by abnormal proliferation, poor cell differentiation, and infiltration of bone …

Tyrosine kinases, enzymes that catalyze the transfer of phosphate from ATP to tyrosine
residues in polypeptides, are ubiquitous, numerous, and of considerable clinical interest …